Navigation Links
Weight a Factor in Breast Cancer Risk After HRT Use

By Amanda Gardner
HealthDay Reporter

TUESDAY, Aug. 10 (HealthDay News) -- Another analysis of data on hormone therapy use among U.S. women finds that the panorama of risks is even more complex than previously thought: Thinner women taking it showed a higher risk of developing breast cancer than heavier women.

The California researchers also found that the longer a woman used either estrogen-alone therapy or estrogen-plus-progestin therapy, the higher the risk of disease. Similar results were seen for women who used combined therapy continuously rather than taking breaks during the month.

"This gives us a clear correlation between the length of treatment and risk," said Dr. Freya Schnabel, director of breast surgery at NYU Langone Medical Center in New York City. "Ad hoc, people had made the assumption that, for the most part, shorter was better, but this definitely gives you some parameters on that."

Given that current recommendations on the use of HRT to relieve menopausal symptoms are to use as little as possible for as short a time as possible, Schnabel said, "this supports that and gives a framework for that."

The findings appear in the current issue of the journal Cancer Epidemiology, Biomarkers & Prevention.

Previous analyses have verified that taking combined estrogen-plus-progestin ups breast cancer risk. In fact, a dramatic tapering off in HRT use after the results of the landmark Women's Health Initiative (WHI) study were published in 2002 has coincided with a decline in the number of invasive breast cancers doctors are seeing.

"There's no question that [the release of information from the WHI] was a cataclysmic moment for HRT in the U.S.," Schnabel said. "A lot fewer women are using it, and what we've seen as a result is that breast cancer rates have gone down, and epidemiologists seem pretty comfortable that it was because of that."

Since those original results, however, researchers have revealed various nuances in which the risk is highest, often corresponding with age and type of formulation used.

For this paper, researchers from the University of Southern California combed through data on hormone therapy among almost 3,000 women who were followed for about 10 years, roughly from 1995 to 2006.

Using estrogen therapy for 15 years or longer increased the risk of breast cancer by 19 percent, compared with women who had never used HRT.

Using combined therapy for this length of time bumped up the risk by 83 percent.

And those women taking combined therapy without interruption had highest risk.

Meanwhile, women with a lower body-mass index (BMI) were more at risk than those with a BMI above 30, which is considered obese, although it wasn't clear why.

Not surprisingly, only women with estrogen-receptor, progesterone-receptor and Her2-neu positive malignancies carried the higher risk.

"This is another example of why, if you're going to take these medicines, you need to take them for as short a period of time as possible and [it shows] that the estrogen-plus-progestin formulations are worse than estrogen alone," said Dr. Jay Brooks, chairman of hematology/oncology at Ochsner Health System in Baton Rouge, La. "These drugs are still licensed in the U.S., but they have black-box warnings on them for a reason, which are an increased risk of stroke, heart attack and, in the estrogen/progestin combination, an increased risk of breast cancer."

"Women have to make decisions about the quality of their life and also about exposure to potentially dangerous drugs," he added.

One of the study authors reported having served as an expert witness in a lawsuit against the maker of Prempro, used to combat hot flashes and other symptoms of menopause.

More information

Visit the National Heart, Lung, and Blood Institute for more on the accruing results of the Women's Health Initiative.

SOURCES: Jay Brooks, M.D., chairman, hematology/oncology, Ochsner Health System, Baton Rouge, La.; Freya Schnabel, M.D., director, breast surgery, NYU Langone Medical Center, New York City; Cancer Epidemiology, Biomarkers & Prevention

Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Excess Weight May Protect Women From Type of Glaucoma
2. Weight Gain Eroding Americans Quality of Life
3. Low Carb-, Low-Fat Diets Tied for Long-Term Weight Loss
4. Study: Weight issues move up need for walkers, canes, other devices
5. Complications From Weight-Loss Surgery Relatively Low
6. To Help Keep Weight Off, Turn to the Web
7. The more frequently you log on, the more weight you can keep off
8. Many knee and hip replacement patients experience weight decrease after surgery
9. Overcoming childhood obesity means addressing moms weight issues as well
10. New Pill Found to Cut Weight With Few Side Effects: Study
11. Excess Weight in Older Women Linked to Diminished Memory
Post Your Comments:
Related Image:
Weight a Factor in Breast Cancer Risk After HRT Use
(Date:11/25/2015)... ... November 25, 2015 , ... ... direct sauna parts and accessories. , Sauna accessories help improve the bather experience ... and personality. From basic styles for the purist looking for simplicity in design ...
(Date:11/25/2015)... ... 2015 , ... For the first time, Vitalalert is donating half of its ... The partnership between the two groups began in 2014 with Vitalalert pledging a portion ... International was founded in 1954 and is an international Christian-based health organization whose mission ...
(Date:11/25/2015)... , ... November 25, 2015 , ... On November 25, ... center for the Narconon network, announced the release of a new cutting edge recovery ... Narconon organization has been working with drug- and alcohol-addicted individuals with the purpose to ...
(Date:11/25/2015)... ... 2015 , ... Smiles by Stevens is pleased to announce the ... While many patients are aware of the benefits of Botox® in the treatment of ... suffering with discomfort, soreness, and pain as a result of Jaw Tension, TMJ (temporo-mandibular ...
(Date:11/25/2015)... (PRWEB) , ... November 25, 2015 , ... In an ... Resurrection Medical Center (RMC) in Chicago, IL, UV Angel is evaluating the efficacy of ... and surgical intensive care units (totaling 30 beds) from May 2014 through October 2015 ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... , Nov. 26, 2015 Research and ... of the "2016 Future Horizons and Growth ... Market: Supplier Shares, Country Segment Forecasts, Competitive Intelligence, ... --> --> ... of the Italian therapeutic drug monitoring market, including ...
(Date:11/25/2015)... Nov. 25, 2015  Amgen (NASDAQ: AMGN ) ... (BLA) with the United States ... a biosimilar candidate to Humira ® (adalimumab). Amgen ... submitted to the FDA and represents Amgen,s first BLA ... E. Harper , M.D., executive vice president of Research ...
(Date:11/25/2015)... MINNEAPOLIS , Nov. 25, 2015  ARKRAY ... care products, continues to provide evidence demonstrating the accuracy ... the World Congress on Insulin Resistance, Diabetes and Cardiovascular ... showed that both the Company,s GLUCOCARD ® 01 ... met high accuracy requirements. The ability to accurately measure ...
Breaking Medicine Technology: